The Hemostatic Effect of Adona (AC-17)

Chr. F Borchgrevink; Ragna Fölling Elgjo; K Hattel; P. F Hjort

doi:10.1055/s-0038-1655399

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1962; 07(03): 499-506
DOI: 10.1055/s-0038-1655399

Originalarbeiten — Original Articles — Travaux Originaux

Schattauer GmbH

The Hemostatic Effect of Adona (AC-17)

Chr. F Borchgrevink

¹Institute for Thrombosis Research, University Hospital, Rikshospitalet, Oslo, Norway (Head: Prof. P. A. Owren) and Vår Frues Hospital, Oslo, Norway (Head: Dr. R. Andersen)

,

Ragna Fölling Elgjo

¹Institute for Thrombosis Research, University Hospital, Rikshospitalet, Oslo, Norway (Head: Prof. P. A. Owren) and Vår Frues Hospital, Oslo, Norway (Head: Dr. R. Andersen)

,

K Hattel

¹Institute for Thrombosis Research, University Hospital, Rikshospitalet, Oslo, Norway (Head: Prof. P. A. Owren) and Vår Frues Hospital, Oslo, Norway (Head: Dr. R. Andersen)

,

P. F Hjort

¹Institute for Thrombosis Research, University Hospital, Rikshospitalet, Oslo, Norway (Head: Prof. P. A. Owren) and Vår Frues Hospital, Oslo, Norway (Head: Dr. R. Andersen)

› Institutsangaben

Abstract

als PDF herunterladen

Summary

In normal individuals 50 mg Adona (AC-17) intravenously increased capillary resistance, and slightly shortened the bleeding time. No effect was observed on coagulation or platelets.

In patients undergoing prostatic surgery the drug seemed to reduce the blood loss during the operation.

50 mg Adona (AC-17) was given to 11 patients with a prolonged bleeding time of various causes, and to 8 patients with a positive tourniquet test. No effect could be demonstrated. However, the drug may be of value in some patients with acquired, ill-defined, presumably vascular diseases.

PDF (1175 kb)

Referenzen

References
1 Andersen R. Benign prostatic obstruction: a series of 250 transvesical prostatectomies. Acta chir. scand 1957; 112: 363-373.
2 Borchgrevink C. F, Waaler B. A. The secondary bleeding time. A new method for the differentiation of hemorrhagic disorders. Acta med. scand 1958; 162: 361-374.
3 Burke D. E, Pogrund R. S, Clark W. G. Hemostatic agents in control of bleeding. Clin. Res 1960; 8: 127
4 Calnan J, Innes F. L. F. Control of bleeding at operation: A trial of adrenochrome monosemicarbazone (Adrenoxyl). Brit. J. plast. Surg 1958; 11: 87-96.
5 Egeberg O. Assay of antihemophilic AB, and C factors by one-stage cephalin systems. Scand. J. clin. Lab. Invest 1961; 13: 140-152.
6 Harris S. H. Suprapubic prostatectomy with closure. Brit. J. Urol 1929; 1: 285-295.
7 Hjort P. F, Stormorken H. A study of the in vitro and in vivo effects of a synthetic heparin-like anticoagulant: dextransuphate. Scand. J. clin. Lab. Invest 1957; 9 (suppl.) (29) 86
8 Jespersen C. M. Adrenoxyl og blödningstendens ved tonsilectomier. Nord. Med 1959; 62: 1430-1432.
9 Marcus J. Aa, Spaet T. H. Ineffectiveness of Adrenosem in pulmonary surgery. J. thorac. Surg 1958; 35: 821-824.
10 Nygaard K. K. A direct method of counting platelets in oxalated plasma. Proc. Mayo Clin 1933; 8: 365-370.
11 Owren P. A, Aas K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand. J. clin. Lab. Invest 1951; 3: 201-208.
12 Peele J. C. Arenosem in the control of haemorrhage from the nose and throat. Arch. Surg 1958; 10: 103-108.
13 Rollas on W. N. Anaesthesia. Adrenoxyl ad perfusionem and the reduction of blood loss. Anaesthesia 1958; 13: 56-59.
14 Roskam J. Arrest of bleeding, Ill. Thomas; Springfield: 1954
15 Ruddell J. S. Adrenochrome monosemicarbazone (adrenoxyl). Anaesthesia 1958; 13: 269-278.
16 Stefanini M, Dameshek W. The hemorrhagic disorders. Grune & Stratton; New York: 1955: 368
17 Stovner J, Brennhovd I. The effect of adrenoxyl on blood loss during radical mastectomy. Acta anaesth. scand 1961; 5: 33-37.
18 Thies H. A. Erfahrungen mit einem japanischen Hämostypticum. Arzneimittel-Forsch. (Drug Res.) 1958; 8: 160-161.
19 Voss D. Untersuchungen zur Gerinnsel-Retraktion. Paper no. 346, 7th Congr. int. Soc. Haemat; Rome: 1958